Personalizing first-line systemic therapy in metastatic colorectal cancer: Is there a role for initial low-intensity therapy in 2021 and beyond? a perspective from members of the Australasian Gastrointestinal Trials Group
Journal Title
Clinical Colorectal Cancer
Publication Type
epub ahead of print
Abstract
Palliative chemotherapy is the cornerstone of treatment for the majority of patients with metastatic colorectal cancer, with the aim of increasing length and quality of life. Although guidelines outline the available treatment options in the first line, they provide limited guidance on choice and intensity of the chemotherapy backbone. Data from the TRIBE and TRIBE2 studies confirm a survival benefit with triplet FOLFOXIRI and bevacizumab, and this is a preferred option for younger patients with good performance status able to tolerate it. However, the relative benefit of a fluoropyrimidine doublet with oxaliplatin or irinotecan over single-agent fluoropyrimidine with or without a biologic is less certain; the available data demonstrate that single-agent fluoropyrimidine plus a biologic with planned sequencing of subsequent agents can produce similar overall survival outcomes with reduced toxicity. Our analysis of local real-world registry data suggests that this is an underutilized approach, particularly in younger and fitter patients. Established prognostic factors, including patient age, performance status, tumor sidedness, and biomarkers such as RAS/BRAF, are key in treatment selection; patients with left-sided RAS/BRAF wild-type disease or patients with low tumor bulk may be ideal for a less intensive regimen. Further studies are required to confirm the value of less-intensive regimens in the modern era, where the incorporation of biologic therapies has become routine and where non-chemotherapy options are emerging as viable options for molecularly defined patient subsets.
Publisher
Elsevier
Keywords
Colorectal cancer; Combination chemotherapy; Doublet chemotherapy; Sequential chemotherapy; Single-agent chemotherapy
WEHI Research Division(s)
Personalised Oncology
PubMed ID
34103264
Rights Notice
Refer to copyright notice on published article.


Creation Date: 2021-06-21 10:25:56
Last Modified: 2021-06-21 10:35:59
An error has occurred. This application may no longer respond until reloaded. Reload 🗙